jasdooit

A YouTuber with visual impairment, known as One Shot Hansol (whose real name is Kim Hansol), has gained attention for applying to a clinical trial at Neuralink, a U.S.-based company founded by Elon Musk.

One Shot Hansol, boasting 1.63 million followers, recently shared on his YouTube channel that he has directly enrolled in the clinical trial for ‘Blindsight,’ a vision-recovery technology being developed by Neuralink. ‘Blindsight’ is a system designed to allow the brain to receive visual data directly, bypassing the eyes. It functions by inserting a small chip into the brain to activate the visual cortex.

One Shot Hansol is a person who has been visually impaired since birth, having lost his sight as a result of issues with his optic nerves. He began noticing problems with his vision while riding a school bus during his high school years in 2010, and by two to three months later, he had completely lost his eyesight.

He said, “It’s not about the eyes perceiving, but the brain interpreting. It’s comparable to science fiction technology. They open the skull and insert a chip the size of a coin into the brain. It involves seeing through a camera mounted on glasses—the computer transmits signals to the chip in the brain, enabling vision. In essence, it’s the brain that sees, not the eyes.”

He stated, “I learned that the procedure is carried out by a robot and lasts approximately an hour,” and mentioned, “The technology is genuinely impressive, yet it could be unsettling if misapplied. I’m also concerned that it might enable someone to access my thoughts or interfere with them.”

He added, “A world where only the wealthy can see and the poor cannot must not come to pass,” and stated, “If I make a lot of money in the future, I want to help cover the surgical expenses for those who need it. If that isn’t possible, I’ll grab Musk by the collar.”

Neuralink, a firm established in 2016 by Elon Musk along with eight scientists and engineers, has been making progress in the creation of implantable brain-computer interfaces (BCI). Human clinical trials received regulatory clearance in May 2023.

• Monday 5900 won membership, 2900 won for newspaper readers, Chosun membership
• 8 titles of newspapers and magazines worth 55,000 won available to read as much as you want, Chosun Membership
• Receive 7000 points to use like cash, shop wisely, Chosun Membership